Effect of candesartan on cause-specific mortality in heart failure patients: The candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM) program (vol 110, pg 2180, 2004)

被引：0
|
作者：
Solomon
机构：
来源：
CIRCULATION | 2005年 / 111卷 / 03期
关键词：
D O I：
10.1161/01.CIR.0000155486.26868.C9
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：378 / 378
页数：1
相关论文
共 50 条
  • [21] Factors precipitating heart failure hospitalisation: a novel analysis of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme
    Mcentegart, M.
    Yusuf, S.
    Pfeffer, M. A.
    Michelson, E. L.
    Ostergren, J.
    Granger, C. B.
    Swedberg, K.
    McMurray, J. J. V.
    EUROPEAN HEART JOURNAL, 2005, 26 : 280 - 280
  • [22] Liver function test abnormalities and outcome in patients with chronic heart failure: Data from the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM) program
    Allen, Larry A.
    Felker, G. Michael
    Pocock, Stuart J.
    McMurray, John J. V.
    Pfeffer, Marc A.
    Swedberg, Karl
    Wang, Duolao
    Yusuf, Salim
    Michelson, Eric L.
    Granger, Christopher B.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (09) : 44A - 44A
  • [23] Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program
    Ariti, Cono A.
    Cleland, John G. F.
    Pocock, Stuart J.
    Pfeffer, Marc A.
    Swedberg, Karl
    Granger, Christopher B.
    McMurray, John J. V.
    Michelson, Eric L.
    Ostergren, Jan
    Yusuf, Salim
    AMERICAN HEART JOURNAL, 2011, 162 (05) : 900 - 906
  • [24] Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure - Results of the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) program
    O'Meara, Eileen
    Clayton, Tim
    McEntegart, Margaret B.
    McMurray, John J. V.
    Pina, Ileana L.
    Granger, Christopher B.
    Ostergren, Jan
    Michelson, Eric L.
    Solomon, Scott D.
    Pocock, Stuart
    Yusuf, Salim
    Swedberg, Karl
    Pfeffer, Marc A.
    CIRCULATION, 2007, 115 (24) : 3111 - 3120
  • [25] Weight loss (but not weight gain) is a strong predictor of mortality in chronic heart failure: Findings from the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM) program
    Kenchaiah, S
    McMurray, JJ
    Pocock, SJ
    Wang, DL
    Solomon, SD
    McEntegart, M
    Michelson, EL
    Granger, CB
    Pfeffer, MA
    CIRCULATION, 2005, 112 (17) : U660 - U660
  • [26] Candesartan improves functional class across a broad spectrum of patients with chronic heart failure:: Results of the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity programme (CHARM)
    McMurray, JJ
    Östergren, J
    Olofsson, B
    Granger, CB
    Michelson, E
    Young, JB
    Dunlap, M
    Yusuf, S
    Swedberg, K
    Pfeffer, MA
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (05) : 206A - 206A
  • [27] Initial data supporting the design of the Candesartan in Heart failure - Assessment of Reduction in Mortality and morbidity (CHARM) programme
    McKelvie, Robert S.
    JOURNAL OF HYPERTENSION, 2006, 24 : S9 - S13
  • [28] Candesartan benefits and safety observed regardless of age. Insights from the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) program.
    Cohen-Solal, Alain
    Swedberg, Karl
    Mc Murray, John
    Pfeffer, Marc
    Olofsson, Bertil
    Michelson, Eric
    Yusuf, Salim
    Granger, Christopher
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (09) : 55A - 55A
  • [29] RESOURCE UTILIZATION AND COSTS FOR CANDESARTAN IN HEART FAILURE: ASSESSMENT OF REDUCTION IN MORTALITY AND MORBIDITY (CHARM) PROGRAMME FOR THE AUSTRIAN SETTING
    Fruhwald, F. M.
    Vavrovsky, A. D.
    VALUE IN HEALTH, 2011, 14 (07) : A379 - A379
  • [30] Benefits of candesartan are consistent regardless of pre-treatment systolic blood pressure in the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) program.
    Meredith, P. A.
    Ostergren, J.
    McMurray, J. J. V.
    Granger, C. B.
    Swedberg, K.
    Yusuf, S.
    Michelson, E. L.
    Olofsson, B.
    Puu, M.
    Solomon, S. D.
    Pfeffer, M. A.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (09) : 331A - 331A
12345